ADENOSINE INJECTION, USP

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

adenosine (UNII: K72T3FS567) (adenosine - UNII:K72T3FS567)

Inapatikana kutoka:

Cardinal Health

INN (Jina la Kimataifa):

adenosine

Tungo:

adenosine 3 mg in 1 mL

Njia ya uendeshaji:

INTRAVENOUS

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. Adenosine injection is contraindicated in:

Bidhaa muhtasari:

Adenosine injection is supplied as a sterile non-pyrogenic solution in normal saline as follows: NDC 17478-542-02, 6 mg/2 mL vial in a carton of 10 (not shrink wrapped). NDC 17478-542-25, 6 mg/2 mL vial in a carton of 25. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. DO NOT REFRIGERATE as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use. Contains no preservatives. Discard unused portion. May require needle or blunt. To prevent needle-stick injuries, needles should not be recapped, purposely bent or broken by hand.

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

ADENOSINE- ADENOSINE INJECTION, SOLUTION
CARDINAL HEALTH
----------
ADENOSINE INJECTION, USP
For Rapid Bolus Intravenous Use
RX ONLY
DESCRIPTION:
Adenosine is an endogenous nucleoside occurring in all cells of the
body. It is chemically 6-amino-9-
β-D-ribofuranosyl-9-H-purine and has the following structural
formula:
Adenosine is a white crystalline powder. It is soluble in water and
practically insoluble in alcohol.
Solubility increases by warming and lowering the pH. Adenosine is not
chemically related to other
antiarrhythmic drugs. Adenosine injection is a sterile, nonpyrogenic
solution for rapid bolus intravenous
injection. Each mL contains 3 mg adenosine, and 9 mg sodium chloride,
in Water for Injection. The pH
of the solution is between 4.5 and 7.5.
CLINICAL PHARMACOLOGY:
MECHANISM OF ACTION
Adenosine injection slows conduction time through the A-V node, can
interrupt the reentry pathways
through the A-V node, and can restore normal sinus rhythm in patients
with paroxysmal supraventricular
tachycardia (PSVT), including PSVT associated with
Wolff-Parkinson-White Syndrome.
Adenosine is antagonized competitively by methylxanthines such as
caffeine and theophylline, and
potentiated by blockers of nucleoside transport such as dipyridamole.
Adenosine is not blocked by
atropine.
HEMODYNAMICS
The intravenous bolus dose of 6 or 12 mg adenosine injection usually
has no systemic hemodynamic
effects. When larger doses are given by infusion, adenosine decreases
blood pressure by decreasing
peripheral resistance.
PHARMACOKINETICS
Intravenously administered adenosine is rapidly cleared from the
circulation via cellular uptake,
primarily by erythrocytes and vascular endothelial cells. This process
involves a specific
transmembrane nucleoside carrier system that is reversible,
nonconcentrative, and bidirectionally
symmetrical. Intracellular adenosine is rapidly metabolized either via
phosphorylation to adenosine
monophosphate by adenosine kinase, or via deamination to inosine by
adenosine deaminase in the
cytosol. Since ad